Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Enliven Therapeutics, Inc.
Report date February 12, 2026 · Filed February 17, 2026
Section 16 reporting ended · disclosed 2026-02-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,750 |
Reported balance
After 2026-02-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 18,750 · Balance 18,750 F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.16 · Expires 2036-02-12 | Direct | 112,500 |
Reported balance
After 2026-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-12 · Grant · Acquired 112,500 · Balance 112,500 F3: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 740,188 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 740,188 F2: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
F3: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2024 Filed May 1, 2024 19:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 10,987 | $17.86 | $196,265.18 |
DisclosureSEC source: 0001415889-24-011915 · form4-05012024_110500.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,013 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.369 to $18.3544. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 29, 2024 Filed May 1, 2024 19:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 12,000 | $1.12 | $13,440.00 |
DisclosureSEC source: 0001415889-24-011915 · form4-05012024_110500.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 19:06 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001415889-24-010830 · form4-04152024_110409.xml · derivative · entry 4 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,550 Underlying: Common Stock · 30,000 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 19:06 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 30,000 | $25.04 | $751,332.00 |
DisclosureSEC source: 0001415889-24-010830 · form4-04152024_110409.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.67. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 19:06 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 30,000 | $1.12 | $33,600.00 |
DisclosureSEC source: 0001415889-24-010830 · form4-04152024_110409.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:30 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001415889-24-010228 · form4-04042024_010402.xml · derivative · entry 6 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,550 Underlying: Common Stock · 12,000 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F6 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:30 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 71 | $19.36 | $1,374.40 |
DisclosureSEC source: 0001415889-24-010228 · form4-04042024_010402.xml · nonDerivative · entry 4 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $19.355 to $19.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:30 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 9,577 | $18.80 | $180,083.99 |
DisclosureSEC source: 0001415889-24-010228 · form4-04042024_010402.xml · nonDerivative · entry 3 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $18.35 to $19.325. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:30 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,352 | $17.72 | $41,687.32 |
DisclosureSEC source: 0001415889-24-010228 · form4-04042024_010402.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,648 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.335 to $18.255. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:30 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 12,000 | $1.12 | $13,440.00 |
DisclosureSEC source: 0001415889-24-010228 · form4-04042024_010402.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 17:55 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001415889-24-006358 · form4-03042024_100311.xml · derivative · entry 5 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 272,550 Underlying: Common Stock · 12,000 shares Expires 2030-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F5 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 17:55 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,805 | $17.09 | $30,854.31 |
DisclosureSEC source: 0001415889-24-006358 · form4-03042024_100311.xml · nonDerivative · entry 3 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $16.86 to $17.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 17:55 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 10,195 | $16.30 | $166,151.99 |
DisclosureSEC source: 0001415889-24-006358 · form4-03042024_100311.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,805 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.86 to $16.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 17:55 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 12,000 | $1.12 | $13,440.00 |
DisclosureSEC source: 0001415889-24-006358 · form4-03042024_100311.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:00 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 185,000 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001415889-24-004024 · form4-02162024_020217.xml · derivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2034-02-12 F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 13, 2025 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:22 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001415889-24-002127 · form4-02012024_020241.xml · derivative · entry 4 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,550 Underlying: Common Stock · 12,000 shares Expires 2030-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:22 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,000 | $15.85 | $190,256.40 |
DisclosureSEC source: 0001415889-24-002127 · form4-02012024_020241.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.58 to $16.375. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:22 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 12,000 | $1.12 | $13,440.00 |
DisclosureSEC source: 0001415889-24-002127 · form4-02012024_020241.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 19:01 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-24-000544 · doc4.xml · derivative · entry 5 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,550 Underlying: Common Stock · 12,000 shares Expires 2030-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F5 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 19:01 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,849 | $14.78 | $42,113.35 |
DisclosureSEC source: 0001209191-24-000544 · doc4.xml · nonDerivative · entry 3 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $14.65 to $15.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 19:01 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 9,151 | $14.13 | $129,267.94 |
DisclosureSEC source: 0001209191-24-000544 · doc4.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,849 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.65 to $14.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 19:01 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 12,000 | $1.12 | $13,440.00 |
DisclosureSEC source: 0001209191-24-000544 · doc4.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 19:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 6,546 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-23-059718 · doc4.xml · derivative · entry 7 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,550 Underlying: Common Stock · 6,546 shares Expires 2030-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 19:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,546 | $13.07 | $85,530.04 |
DisclosureSEC source: 0001209191-23-059718 · doc4.xml · nonDerivative · entry 4 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 19:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 6,546 | $1.12 | $7,331.52 |
DisclosureSEC source: 0001209191-23-059718 · doc4.xml · nonDerivative · entry 3 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 19:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 20 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-23-059718 · doc4.xml · derivative · entry 6 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,096 Underlying: Common Stock · 20 shares Expires 2030-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 19:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 20 | $13.00 | $260.00 |
DisclosureSEC source: 0001209191-23-059718 · doc4.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 19:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 20 | $1.12 | $22.40 |
DisclosureSEC source: 0001209191-23-059718 · doc4.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 16:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 8,688 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-23-059432 · doc4.xml · derivative · entry 7 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,116 Underlying: Common Stock · 8,688 shares Expires 2030-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 16:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 8,688 | $13.01 | $113,045.65 |
DisclosureSEC source: 0001209191-23-059432 · doc4.xml · nonDerivative · entry 4 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 16:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 8,688 | $1.12 | $9,730.56 |
DisclosureSEC source: 0001209191-23-059432 · doc4.xml · nonDerivative · entry 3 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 16:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 200 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-23-059432 · doc4.xml · derivative · entry 6 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 323,804 Underlying: Common Stock · 200 shares Expires 2030-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 16:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 200 | $13.00 | $2,600.00 |
DisclosureSEC source: 0001209191-23-059432 · doc4.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 16:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 200 | $1.12 | $224.00 |
DisclosureSEC source: 0001209191-23-059432 · doc4.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 16:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 8,546 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-23-054525 · doc4.xml · derivative · entry 4 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 324,004 Underlying: Common Stock · 8,546 shares Expires 2030-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 16:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 8,546 | $13.08 | $111,750.91 |
DisclosureSEC source: 0001209191-23-054525 · doc4.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.195. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 16:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 8,546 | $1.12 | $9,571.52 |
DisclosureSEC source: 0001209191-23-054525 · doc4.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 19:40 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-23-051732 · doc4.xml · derivative · entry 4 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 332,550 Underlying: Common Stock · 12,000 shares Expires 2030-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 19:40 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 12,000 | $13.62 | $163,497.60 |
DisclosureSEC source: 0001209191-23-051732 · doc4.xml · nonDerivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.315 to $13.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 19:40 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 12,000 | $1.12 | $13,440.00 |
DisclosureSEC source: 0001209191-23-051732 · doc4.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:33 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 206,000 | $0.00 Strike: $22.75 | $0.00 |
DisclosureSEC source: 0001209191-23-023678 · doc4.xml · derivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,000 Underlying: Common Stock · 206,000 shares Expires 2033-04-04 F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 23, 2024 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:34 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantEmployee Stock Option (right to buy) · Derivative | 88,531 | Not disclosed Strike: $2.48 | Not disclosed |
DisclosureSEC source: 0001209191-23-013495 · doc4.xml · derivative · entry 3 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,531 Underlying: Common Stock · 88,531 shares Expires 2031-03-25 F4 · price: In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). F5 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on January 14, 2021. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:34 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantEmployee Stock Option (right to buy) · Derivative | 344,550 | Not disclosed Strike: $1.12 | Not disclosed |
DisclosureSEC source: 0001209191-23-013495 · doc4.xml · derivative · entry 2 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,550 Underlying: Common Stock · 344,550 shares Expires 2030-06-15 F4 · price: In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). F3 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:34 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantCommon Stock | 1,117,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-013495 · doc4.xml · nonDerivative · entry 1 Lyssikatos Joseph P · CIK 0001967150 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,117,035 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the "Merger"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed "Enliven Therapeutics, Inc." and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol "ELVN." F2 · ownership.nature: The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the reporting person serves as trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.